Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

Table 1 Whole exome sequencing of patients-derived biopsies and xenografts

Sample	Yield (Gbases)	Reads (× 10⁶)	% ≥ Q30 bases (PF)	Key mutations
Biopsy from patient CTC15035_EML4–ALK	13.63	90.88	90.73	EML4–ALK fusion (EML4 exon18–ALK exon 20)
Crizotinib-6 xenograft	27.77	185.10	91.38	EML4–ALK fusion (EML4 exon18–ALK exon 20); ALK: E1210K (9%)
Biopsy from patient CTC15063_{EGFR L858R, T790M}	14.72	98.15	90.94	EGFR: L858R (85.7%) and T790M (71.5%)
Xenograft from patient CTC15063_{EGFR L858R, T790M}	25.09	167.24	90.04	EGFR: L858R (83.3%) and T790M (77.6%)
Osimertinib-3 xenograft	27.38	182.52	90.73	EGFR: L858R (53.6%) and T790M (41.7%); PIK3C2A: R86fs (11%); BRAF: G7V (11.5%)

Gbases gigabases, M million, PF post filter, EML4–ALK echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase, EGFR epidermal growth factor receptor

ISSN: 2523-3548